Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)

Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)

The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.

Inclusion Criteria:

• Diagnosis of atopic dermatitis according to Hanifin and Rajka criteria
• Body surface area affected by atopic dermatitis at or less than 15% at start of treatment

Exclusion Criteria:

• Pregnancy and breast-feeding
• Conditions that may pose a threat to the patient or effect the outcome of the study
• Wide-spread atopic dermatitis (AD) requiring systemic treatment
• Immuno-compromized conditions
• At least 2 weeks after local AD treatment and treatment with systemic antibiotics
• At least 1 month after systemic AD treatment